The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease

• Status: Unknown status
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to assess the effects of the drug lanthanum carbonate (a phosphorus binder drug) on c-terminal and on FGF23 levels in patients with Chronic Kidney Disease (CKD).

Targeting FGF23 measurement in CKD patients may impact both the progression of kidney disease and patient mortality.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NorthShore University HealthSystem; NorthShore University HealthSystem Research Institute
• Collaborator: Shire
• Treatments: Mitogens

Criteria

Inclusion Criteria:

• Males and non-pregnant females ages 18 years of age or older

• Estimated GFR between 15-60 ml/min/1.73m

• Serum phosphate > 3.5 mg/dL

• FGF2 > 100RU/mL

• Corrected serum clacium >8.0mg/dL

Exclusion Criteria:

• Current use of a phosphate binder

• Corrected serum calcium <8.0mg/dL

• Current use of prescription-based vitamin D therapy

• Acute kidney injury in last 3 months

• Significant GI disorder

• History of allergic reaction or sensitivity to lanthanum carbonate

• History of non compliance with visits or medications that preclude study compliance in the opinion of the investigator

• Pregnant or able to become pregnant and unwilling to use a birth control method considered reliable by the principal investigator